バイオマーカーの世界市場予測（～2021年）：安全性マーカー、予測マーカー、代替マーカー、薬力学マーカー、予後マーカー...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 13
1.3.1 MARKETS COVERED 14
1.3.2 YEARS CONSIDERED IN THE REPORT 15
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.2.1 KEY DATA FROM SECONDARY SOURCES 22
2.2.2 KEY DATA FROM PRIMARY SOURCES 22
2.3 MARKET RANK ESTIMATION 23
2.4 KEY INDUSTRY INSIGHTS 23
2.5 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 29
4.1 BIOMARKERS: MARKET OVERVIEW 29
4.2 GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET, BY PRODUCT (2016) 30
4.3 BIOMARKERS MARKET, BY TYPE, 2016 VS. 2021 31
4.4 BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 31
4.5 BIOMARKERS MARKET, BY DISEASE INDICATION, 2016 VS. 2021 32
4.6 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 32
4.7 LIFE CYCLE ANALYSIS, BY REGION, 2016 33

5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increasing diagnostic applications of biomarkers 36
5.2.1.1.1 Personalized medicine 36
5.2.1.1.2 Companion diagnostics 36
 
5.2.1.2 Increasing R&D funding for pharma and biotech companies 37
5.2.1.3 Increasing number of CROs and low cost of clinical trials in developing countries 38
5.2.1.4 High prevalence of cancer 38
5.2.1.5 New initiatives for biomarker research 40
5.2.2 RESTRAINTS 40
5.2.2.1 High capital investments and low cost-benefit ratio 40
5.2.2.2 Poorly suited regulatory and reimbursement systems 41
5.2.2.3 Technical issues related to sample collection and storage 41
5.2.3 OPPORTUNITIES 42
5.2.3.1 Emerging economies 42
5.2.4 CHALLENGES 42
5.2.4.1 Proving the clinical validity in biomarker-based tests 42

6 BIOMARKERS MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 CONSUMABLES 45
6.3 SERVICES 46
6.4 SOFTWARE 48

7 BIOMARKERS MARKET, BY TYPE 50
7.1 INTRODUCTION 51
7.2 SAFETY BIOMARKERS 52
7.3 EFFICACY BIOMARKERS 54
7.3.1 PREDICTIVE BIOMARKERS 57
7.3.2 SURROGATE BIOMARKERS 58
7.3.3 PHARMACODYNAMIC BIOMARKERS 59
7.3.4 PROGNOSTIC BIOMARKERS 60
7.4 VALIDATION BIOMARKERS 61

8 BIOMARKERS MARKET, BY APPLICATION 63
8.1 INTRODUCTION 64
8.2 DIAGNOSTICS 65
8.3 DRUG DISCOVERY AND DEVELOPMENT 67
8.4 PERSONALIZED MEDICINE 69
8.5 DISEASE RISK ASSESSMENT 71
8.6 OTHER APPLICATIONS 73

9 BIOMARKERS MARKET, BY DISEASE INDICATION 76
9.1 INTRODUCTION 77
9.2 CANCER 78
9.3 CARDIOVASCULAR DISORDERS 81
9.4 NEUROLOGICAL DISORDERS 83
9.5 IMMUNOLOGICAL DISORDERS 84
9.6 OTHER DISEASES 86

10 BIOMARKERS MARKET, BY REGION 89
10.1 INTRODUCTION 90
10.2 NORTH AMERICA 92
10.2.1 U.S. 95
10.2.2 CANADA 98
10.3 EUROPE 101
10.4 ASIA 104
10.4.1 CHINA 108
10.4.2 JAPAN 111
10.4.3 REST OF ASIA 113
10.5 REST OF THE WORLD (ROW) 115

11 COMPETITIVE LANDSCAPE 118
11.1 OVERVIEW 118
11.2 COMPETITIVE SITUATION AND TRENDS 119
11.2.1 PRODUCT LAUNCHES 120
11.2.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 121
11.2.3 ACQUISITIONS 122
11.2.4 OTHER DEVELOPMENTS 122
11.3 LEADING PLAYERS IN THE BIOMARKERS MARKET 123

12 COMPANY PROFILES 124
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 QIAGEN N.V. 125
12.2 PERKINELMER, INC. 128
12.3 MERCK MILLIPORE 131
12.4 BIO-RAD LABORATORIES, INC. 134
12.5 ENZO BIOCHEM, INC. 136
12.6 EKF DIAGNOSTICS HOLDINGS, INC. 139
12.7 MESO SCALE DIAGNOSTICS, LLC. 141
12.8 BIOSIMS TECHNOLOGIES SAS 142
12.9 CISBIO BIOASSAYS 143
12.10 SIGNOSIS, INC. 145
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
 

13 APPENDIX 146
13.1 INSIGHTS OF INDUSTRY EXPERTS 146
13.2 DISCUSSION GUIDE 147
13.3 OTHER DEVELOPMENTS 149
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 151
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 153
13.6 AVAILABLE CUSTOMIZATIONS 155
13.7 RELATED REPORTS 156
13.8 AUTHOR DETAILS 157